Sarepta Therapeutics, Inc. SRPT Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $2.2B— | —— | $1.24B+33.3% | $933.01M+32.9% | ||
| —— | —— | $182.51M— | —— | ||
| $44.52M+18.0% | $37.72M+66.5% | $22.66M+3,073% | $714K+1.1% | ||
| —— | $235.24M+140% | -$581.63M+17.3% | -$703.49M-68.0% | ||
| —— | —— | $182.51M— | —— | ||
| $25.51M-10.7% | $28.55M— | —— | $0— | ||
| $37.63M+66.6% | $22.59M+49.8% | $15.08M— | —— | ||
| -$206.25M-202% | $201.66M+8.6% | $185.7M+190% | $63.98M+23.9% | ||
| $319.57M-19.1% | $395.17M+168% | $147.71M+191% | $50.78M-39.4% | ||
| —— | —— | -$1.81M-106% | $27.94M+127% | ||
| $14.91M-5.9% | $15.86M-0.4% | $15.92M-64.2% | $44.42M-20.6% | ||
| -$168.34M-235% | $124.81M-0.2% | $125M-46.2% | $232.51M-58.6% | ||
| —— | —— | -$165.8M— | —— | ||
| —— | —— | -$500.99M-54.0% | -$325.35M+26.6% | ||
| -$8.31M— | —— | —— | —— | ||
| —— | $1.1B-46.2% | $2.04B+5.6% | $1.94B— | ||
| $7.88M— | —— | $11.24M— | —— | ||
| $101.97M-25.5% | $136.96M+80.0% | $76.11M+147% | $30.82M-19.9% | ||
| $295.87M-85.2% | $2B+7.2% | $1.87B+102% | $923.22M+98.1% | ||
| $123.4M-33.0% | $184.3M+1.0% | $182.51M-21.7% | $233.02M+105% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Sarepta Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.